keyword
MENU ▼
Read by QxMD icon Read
search

Tumors neuroendocrine

keyword
https://www.readbyqxmd.com/read/28651368/risk-of-recurrence-in-pituitary-neuroendocrine-tumors-a-prospective-study-using-a-five-tiered-classification
#1
Gérald Raverot, Emmanuelle Dantony, Julie Beauvy, Alexandre Vasiljevic, Sara Mikolasek, Françoise Borson-Chazot, Emmanuel Jouanneau, Pascal Roy, Jacqueline Trouillas
Background: Most pituitary neuroendocrine tumors (PitNET) show benign behavior, but a significant number are invasive, recur or resist to medical treatment. Based on a retrospective case-control study we recently proposed a classification of PitNETs of prognostic relevance. This prospective study aims to test the value of this classification in an independent patient cohort. Methods: The cohort included patients of a single center operated upon a PitNET. Using a grading system based on invasion on MRI, immunocytochemical profile (ICC), Ki-67, mitotic index, and p53 positivity, tumors were classified...
June 23, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28650600/clear-cell-neuroendocrine-tumor-of-the-pancreas-in-von-hippel-lindau-disease-a-case-report-and-literature-review
#2
(no author information available yet)
Clear cell neuroendocrine tumor (NET) of the pancreas is found in von Hippel-Lindau (VHL) disease, multiple endocrine neoplasia type I (MEN I), and sporadic form. Clear cell NETs are often misdiagnosed as metastatic renal cell carcinoma. A 47-year-old woman with VHL was found to have a mass in the pancreatic tail and two masses in the right kidney with two cysts. A distal pancreatectomy and right radical nephrectomy were performed. The pancreatic lesion was a well-circumscribed, golden-yellow solid mass, which was lobulated by septal fibrosis...
May 26, 2017: Neuro Endocrinology Letters
https://www.readbyqxmd.com/read/28650564/the-impact-of-extrahepatic-disease-among-patients-undergoing-liver-directed-therapy-for-neuroendocrine-liver-metastasis
#3
Aslam Ejaz, Brad N Reames, Shishir Maithel, George A Poultsides, Todd W Bauer, Ryan C Fields, Matt Weiss, Hugo Pinto Marques, Luca Aldrighetti, Timothy M Pawlik
INTRODUCTION: Management of neuroendocrine liver metastasis (NELM) in the presence of extrahepatic disease (EHD) is controversial. We sought to examine outcomes of patients undergoing liver-directed therapy (resection, ablation, or both) for NELM in the presence of EHD using a large international cohort of patients. METHODS: 612 patients who underwent liver-directed therapy were identified from eight institutions. Postoperative outcomes, as well as and overall (OS) were compared among patients with and without EHD...
June 26, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28650392/o6-methylguanine-dna-methyltransferase-status-does-not-predict-response-or-resistance-to-alkylating-agents-in-well-differentiated-pancreatic-neuroendocrine-tumors
#4
Nitya Raj, David S Klimstra, Natally Horvat, Liying Zhang, Joanne F Chou, Marinela Capanu, Olca Basturk, Richard Kinh Gian Do, Peter J Allen, Diane Reidy-Lagunes
OBJECTIVES: Alkylating agents have activity in well-differentiated pancreatic neuroendocrine tumors (WD panNETs). In glioblastoma multiforme, decreased activity of O-methylguanine DNA methyltransferase (MGMT) predicts response; in panNETs, MGMT relevance is unknown. METHODS: We identified patients with WD panNETs treated with alkylating agents, determined best overall response by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, and performed MGMT activity testing...
June 22, 2017: Pancreas
https://www.readbyqxmd.com/read/28650388/everolimus-effect-on-gastrin-and-glucagon-in-pancreatic-neuroendocrine-tumors
#5
Marianne E Pavel, David Chen, Wei He, Stephanie Cushman, Maurizio Voi, Elisabeth G E de Vries, Eric Baudin, James C Yao
OBJECTIVES: The pharmacodynamic effects of everolimus on gastrointestinal hormone levels have not been described in patients with pancreatic neuroendocrine tumors (pNETs). We report the effects of everolimus on gastrin and glucagon levels in patients with progressive pNET in RADIANT-1 (a single-arm phase II trial) and RADIANT-3 (a placebo-controlled, randomized, phase III trial). METHODS: Serum gastrin and glucagon levels were determined by immunoassay at baseline and at predose in subsequent treatment cycles in patients with elevated baseline hormone levels...
June 22, 2017: Pancreas
https://www.readbyqxmd.com/read/28649475/solid-pseudopapillary-tumor-of-the-pancreas-an-unusual-cause-of-abdominal-pain
#6
Talal El Imad, Fady G Haddad, Mayurathan Kesavan, Liliane Deeb, Sherif Andrawes
Solid-pseudopapillary neoplasm (SPN) of the pancreas is a rare tumor that accounts for less than one percent of pancreatic tumors. The diagnosis could be challenging as SPN tend to manifest with nonspecific abdominal symptoms, variable radiological features, and inconsistent morphology. The cellular origin of SPN is unclear and might involve ductal, acinar and endocrine stem cells.  We report a rare case of a 27-year-old female who presented with intermittent abdominal pain for two years, associated with a decrease in appetite...
May 16, 2017: Curēus
https://www.readbyqxmd.com/read/28648398/insulin-expressing-pancreatic-neuroendocrine-tumor-associated-with-intratumor-amyloidosis
#7
Rohini R Vanga, Sadhna Dhingra, Kalpesh Patel
No abstract text is available yet for this article.
June 22, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28647212/combined-primary-hepatic-neuroendocrine-carcinoma-and-hepatocellular-carcinoma-with-aggressive-biological-behavior-adverse-clinical-course-a-case-report
#8
Yukihiko Okumura, Kenichi Kohashi, Huanlin Wang, Masaki Kato, Yoshihiko Maehara, Yoshihiro Ogawa, Yoshinao Oda
Combined primary hepatic neuroendocrine carcinoma (PHNEC) and hepatocellular carcinoma (HCC) is a very rare malignant hepatic tumor. Its prognosis and histological features are uncertain. Here we report the case of such a tumor in a 70-year-old male Japanese patient with adverse prognosis. The patient underwent a right hepatic lobectomy for a tumor mass that measured 11×10cm in diameter located in the right lobe of the liver, treated with transcatheter arterial chemoembolization (TACE) and percutaneous transhepatic portal vein embolization (PTPE) therapy five weeks before the operation...
June 10, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28643736/the-pitfalls-in-cytology-diagnosis-of-poorly-differentiated-neuroendocrine-carcinoma-of-lung-and-their-treatment-response
#9
Debarshi Saha, Ankit Kumar, Sourjya Banerjee, M Nirupama, H B Sridevi, Priya Garg, Flora D Lobo
CONTEXT: Lung is the most common site of small cell carcinoma (SCLC) - a poorly differentiated neuroendocrine carcinoma (PDNEC). SCLC comprises 15-20% of the invasive cancers of the lung. AIM: This study was conducted to appraise the accuracy and pitfalls of the diagnosis of PDNEC on cytology along with treatment responses if available. SETTINGS AND DESIGN: Retrospective study for 2 years yielded 21 cases on cytology. SUBJECTS AND METHODS: Slides of fine-needle aspiration of lymph nodes, the tumor, bronchial brush, and bronchoalveolar lavage specimens were used...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28643173/immunotherapy-and-targeted-therapy-for-small-cell-lung-cancer-there-is-hope
#10
REVIEW
Jonathan M Lehman, Mary E Gwin, Pierre P Massion
Small cell lung cancer (SCLC) is a devastating and aggressive neuroendocrine carcinoma of the lung. It accounts for ~15% of lung cancer mortality and has had no improvement in standard treatment options for nearly 30 years. However, there is now hope for change with new therapies and modalities of therapy. Immunotherapies and checkpoint inhibitors are entering clinical practice, selected targeted therapies show promise, and "smart bomb"-based drug/radioconjugates have led to good response in early clinical trials...
July 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28642484/mir-100-5p-inhibition-induces-apoptosis-in-dormant-prostate-cancer-cells-and-prevents-the-emergence-of-castration-resistant-prostate-cancer
#11
Noushin Nabavi, Nur Ridzwan Nur Saidy, Erik Venalainen, Anne Haegert, Abhijit Parolia, Hui Xue, Yuwei Wang, Rebecca Wu, Xin Dong, Colin Collins, Francesco Crea, Yuzhuo Wang
Carcinoma of the prostate is the most common cancer in men. Treatment of aggressive prostate cancer involves a regiment of radical prostectomy, radiation therapy, chemotherapy and hormonal therapy. Despite significant improvements in the last decade, the treatment of prostate cancer remains unsatisfactory, because a significant fraction of prostate cancers develop resistance to multiple treatments and become incurable. This prompts an urgent need to investigate the molecular mechanisms underlying the evolution of therapy-induced resistance of prostate cancer either in the form of castration-resistant prostate cancer (CRPC) or transdifferentiated neuroendocrine prostate cancer (NEPC)...
June 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28642335/carcinoid-syndrome-and-costs-of-care-during-the-first-year-after-diagnosis-of-neuroendocrine-tumors-among-elderly-patients
#12
Chan Shen, Yiyi Chu, Daniel M Halperin, Arvind Dasari, Shouhao Zhou, Ying Xu, James C Yao, Ya-Chen Tina Shih
BACKGROUND: Neuroendocrine tumors (NETs) can secrete hormonal peptides that lead to additional symptom burdens. However, it is largely unknown whether and to what extent the additional symptom burdens translate into higher costs of care. This study aimed to examine the cost pattern of elderly NET patients during the first year of diagnosis, taking into account of the carcinoid syndrome status. METHODS: We used Surveillance, Epidemiology, and End Results Medicare data to identify elderly NET patients diagnosed between January 2003 and December 2011...
June 22, 2017: Oncologist
https://www.readbyqxmd.com/read/28639924/cushing-syndrome-diagnostic-workup-and-imaging-features-with-clinical-and-pathologic-correlation
#13
Nicolaus A Wagner-Bartak, Ali Baiomy, Mouhammed Amir Habra, Shalini V Mukhi, Ajaykumar C Morani, Brinda R Korivi, Steven G Waguespack, Khaled M Elsayes
OBJECTIVE: Cushing syndrome (CS) is a constellation of clinical signs and symptoms resulting from chronic exposure to excess cortisol, either exogenous or endogenous. Exogenous CS is most commonly caused by administration of glucocorticoids. Endogenous CS is subdivided into two types: adrenocorticotropic hormone (ACTH) dependent and ACTH independent. CONCLUSION: Cushing disease, which is caused by a pituitary adenoma, is the most common cause of ACTH-dependent CS for which pituitary MRI can be diagnostic, with bilateral inferior petrosal sinus sampling useful in equivocal cases...
July 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28639083/tumor-vascularization-and-clinicopathologic-parameters-as-prognostic-factors-in-merkel-cell-carcinoma
#14
A Bob, F Nielen, J Krediet, J Schmitter, D Freundt, D Terhorst, J Röwert-Huber, J Kanitakis, E Stockfleth, Ch Ulrich, M Weichenthal, F Egberts, B Lange-Asschenfeldt
PURPOSE: Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine tumor of the skin with an increasing incidence. The clinical course is variable and reliable prognostic factors are scarce. Tumor angiogenesis has been shown to have prognostic impact in different types of cancer. The aim of our study was to determine potential prognostic factors, including tumor vascularization, for clinical outcome of MCC. METHODS: The medical records of 46 patients with MCC diagnosed between 1997 and 2010 were analyzed retrospectively...
June 21, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28638801/pancreatic-neuroendocrine-tumor-grade-1-patients-followed-up-without-surgery-case-series
#15
Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Yuichi Waragai, Mika Takasumi, Satoshi Kawana, Yuko Hashimoto, Takuto Hikichi, Hiromasa Ohira
Among the three grades of neuroendocrine tumors (NETs), the prognosis for Grade 1 (G1) with surgery is very good. Therefore, we evaluated the prognoses of pancreatic NET (PNET) G1 patients without surgery. A total of 8 patients who were diagnosed with NET G1, with an observation period of more than 6 mo until surgery or without surgery, were recruited. The patients who underwent surgery were ultimately diagnosed using specimens obtained during the surgery, whereas the patients who did not undergo surgery were diagnosed using specimens obtained by endoscopic ultrasonography-guided fine needle aspiration...
June 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28638725/administration-of-a-vasoactive-intestinal-peptide-antagonist-enhances-the-autologous-anti-leukemia-t-cell-response-in-murine-models-of-acute-leukemia
#16
Christopher T Petersen, Jian-Ming Li, Edmund K Waller
Vasoactive intestinal peptide (VIP) is a neuroendocrine peptide hormone that has potent anti-inflammatory activities. VIP signaling through its receptor VPAC1 on T cells leads to reduced proliferation and a reduction in pro-inflammatory cytokine secretion. We report here that inhibition of the VIP pathway with a peptide antagonist significantly enhances a T-cell-dependent, autologous anti-leukemia response in murine models of acute myeloid leukemia and T lymphoblastic leukemia. Subcutaneous administration of the VIP antagonist, VIPhyb, resulted in reduced tumor burden and significantly enhanced survival (30-50% survival) over vehicle-treated controls (0-20% survival)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28638669/external-beam-radiation-and-brachytherapy-for-prostate-cancer-is-it-a-possible-trigger-of-large-cell-neuroendocrine-carcinoma-of-the-urinary-bladder
#17
Ali Zakaria, Bayan Al Share, Sri Kollepara, Cynthia Vakhariya
Neuroendocrine tumors commonly involve the respiratory and gastrointestinal systems. Primary genitourinary neuroendocrine tumors are rare, accounting for less than 1% of all bladder carcinomas. Four histopathologic subtypes have been described. Among those, large cell neuroendocrine carcinoma (LCNEC) is the least common, is more aggressive, and generally presents in an advanced stage with poor prognosis compared to transitional cell bladder carcinoma. There is no standardized treatment regimen because of the rarity of the disease...
2017: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/28637502/clinicopathologic-characteristics-and-prognosis-of-gastroenteropancreatic-neuroendocrine-neoplasms-a-multicenter-study-in-south-china
#18
Cheng Fang, Wei Wang, Yu Zhang, Xingyu Feng, Jian Sun, Yujie Zeng, Ye Chen, Yong Li, Minhu Chen, Zhiwei Zhou, Jie Chen
BACKGROUND: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of rare tumors. Many issues in terms of epidemiologic features, pathogenesis, and treatment of GEP-NENs are still under discussion. Our study aimed to analyze the clinicopathologic characteristics and prognosis of Chinese patients with GEP-NENs. METHODS: Complete clinicopathologic data and survival information of 1183 patients with GEP-NENs treated between 2005 and 2015 were collected from five medical centers in Guangdong Province, China...
June 21, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28635990/neuroendocrine-neoplasms-of-the-head-and-neck-and-olfactory-neuroblastoma-diagnosis-and-classification
#19
S Uccella, G Ottini, C Facco, R Maragliano, S Asioli, F Sessa, S La Rosa
Neuroendocrine neoplasms (NENs) of the head and neck are a rare group of heterogeneous epithelial neoplastic proliferations arising in virtually all of the different organs of this region, particularly in the nasal cavity, the paranasal sinuses, the nasopharynx, the larynx, the salivary glands, and the middle ear. They encompass a wide spectrum of entities ranging from very indolent neuroendocrine tumors to highly aggressive neuroendocrine carcinomas. They may represent a challenge for radiologists, oncologists, and pathologists and a correct diagnosis is crucial for the management of patients...
March 2017: Pathologica
https://www.readbyqxmd.com/read/28634872/predictive-markers-of-response-to-everolimus-and-sunitinib-in-neuroendocrine-tumors
#20
Diana Martins, Francesca Spada, Ioana Lambrescu, Manila Rubino, Chiara Cella, Bianca Gibelli, Chiara Grana, Dario Ribero, Emilio Bertani, Davide Ravizza, Guido Bonomo, Luigi Funicelli, Eleonora Pisa, Dario Zerini, Nicola Fazio
Neuroendocrine tumors (NETs) represent a large and heterogeneous group of malignancies with various biological and clinical characteristics, depending on the site of origin and the grade of tumor proliferation. In NETs, as in other cancer types, molecularly targeted therapies have radically changed the therapeutic landscape. Recently two targeted agents, the mammalian target of rapamycin inhibitor everolimus and the tyrosine kinase inhibitor sunitinib, have both demonstrated significantly prolonged progression free survival in patients with advanced pancreatic NETs...
June 21, 2017: Targeted Oncology
keyword
keyword
68229
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"